Covid-19 Insilico medicine24 Mar 2020 21:40
SAN DIEGO, March 24, 2020 /PRNewswire/ -- Viriom Inc today announces the company's activities to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Elpida (elsulfavirine) and Viriom's experimental flu medicines AV5080, AV5124 and AV5126 to determine their efficacy in the treatment of COVID-19.
The company is collaborating with Chinese Center for Disease Control and Prevention and the Ministry of Health in Russia and select health authorities and institutions in US and globally to determine the antiviral activity of Elpida and several other drug candidates against COVID-19. Viriom is evaluating Chinese and Russian claims that Elpida could be effective in COVID-19 treatment.
Along with industry partners from China Medical Systems Holdings, INSILICO MEDICINE in Hong Kong and Molsoft in San Diego, Viriom is collaborating with PLA Military Academy and Zhejiang University in China, ChemRar Group, Gamaleya Research Institute of Epidemiology and Microbiology, Research Center Institute of Immunology in Russia, Osang Healthcare in South Korea to support research of targeted medicines with novel mechanisms of action against COVID-19 and other pathogenic RNA viruses.
"We are committed to address the COVID-19 public health crisis, which is why we responded quickly to Chinese and Russian authorities' request for Elpida and other drugs testing in February," said Nikolay Savchuk, chairman and president, Viriom. "We are working with global health authorities to ensure we meet the need of COVID-19 patients, conduct the appropriate non clinical and clinical trials to evaluate its efficacy and ensure uninterrupted supply of Elpida for HIV patients around the world."
Sign In
Follow the stocks
